Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

This study is testing whether patients with chronic myeloid leukemia (CML) — a type of blood cancer — can safely stop taking their leukemia medication (a TKI) a second time after previously failing a first attempt, especially when using a newer drug called asciminib to help achieve deeper remission first. **You may be eligible if:** - You are 18 or older with CML in the chronic (stable) phase - You previously attempted to stop your leukemia medication once before and the cancer came back - You were retreated and have now reached a very deep remission (very low to undetectable cancer levels in the blood) - You have been on a TKI medication such as imatinib, dasatinib, or nilotinib - You have adequate kidney, liver, and blood counts **You may NOT be eligible if:** - Your CML has ever been in a more aggressive phase (accelerated or blast phase) - You have a history of pancreatitis in the past year - You have previously been treated with asciminib - You have had a prior stem cell transplant - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.